Concepedia

Author

Jelle Wesseling

The Netherlands Cancer InstituteORCID

Also Known As

Daniel W. Rea, Ignasi Roig I. Qulis, J G Wesseling, J Wesseling, J. WESSELING, J. Wesseling, J.G. Wesseling, Jane Brock, Jelle Wesseling, Laura J. Esserman

645

Publications

22K

Citations

73

H-Index

128

Concepts

All Affiliations

The Netherlands Cancer InstituteOncode InstituteUniversity Medical Center UtrechtLeiden University Medical CenterUniversity Medical Center Groningen
JW

About

Jelle Wesseling is an author at The Netherlands Cancer Institute specializing in medicine, breast cancer, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

45

90

6.5K

2

Health Sciences

18

23

1.3K

3

Engineering

11

11

916

4

Natural Sciences

3

3

422

5

Nursing

1

1

54

Jelle Wesseling

×

220

Publications

16.5K

Citations

67

H-Index

YearCitations

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

Chong Sun, Liqin Wang, Sidong Huang,

Nature

2014

896

Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components.

Jelle Wesseling, S W van der Valk, Hans L. Vos,

The Journal of Cell Biology

1995

494

Marking Axillary Lymph Nodes With Radioactive Iodine Seeds for Axillary Staging After Neoadjuvant Systemic Treatment in Breast Cancer Patients

Mila Donker, Marieke E. Straver, Jelle Wesseling,

Annals of Surgery

2014

415

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

Mette S. van Ramshorst, Anna van der Voort, Erik van Werkhoven,

The Lancet Oncology

2018

413

A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1.

Jelle Wesseling, S W van der Valk, John Hilkens

Molecular Biology of the Cell

1996

384

Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – The LORD study

Lotte E. Elshof, Konstantinos Tryfonidis, Leen Slaets,

European Journal of Cancer

2015

369

Magnetic Resonance Imaging Response Monitoring of Breast Cancer During Neoadjuvant Chemotherapy: Relevance of Breast Cancer Subtype

Claudette E. Loo, Marieke E. Straver, Sjoerd Rodenhuis,

Journal of Clinical Oncology

2011

299

Somatic mutations in the chromatin remodeling gene <i>ARID1A</i> occur in several tumor types

Siân Jones, Meng Li, D. Williams Parsons,

Human Mutation

2011

283

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)

Jolien M. Bueno-de-Mesquita, Wim H. van Harten, Valesca P. Retèl,

The Lancet Oncology

2007

277

Tumour-specific proline vulnerability uncovered by differential ribosome codon reading

Fabricio Loayza‐Puch, Koos Rooijers, Levi C.M. Buil,

Nature

2016

276

Page 1